DOCSLIB.ORG

Supplemental Table 1. GAPDH 5'- CAT GTT CGT CAT GGG TGT GAA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Table 1. GAPDH 5'- CAT GTT CGT CAT GGG TGT GAA Supplemental Table 1. GAPDH 5'- CAT GTT CGT CAT GGG TGT GAA CCA -3' (fwd) 5'- AGT GAT GGC ATG GAC TGT GGT CAT -3' (rev) EPB4L3 5'- AGT GAG TTC CGC TTT GCA CCA AAC -3' (fwd) 5'- AAA TGC ATC TCT GCT TCT GCT GGC -3' (rev) UBE2L6 5'- AGT ATC CGT TCA AGC CTC CCA TGA -3' (fwd) 5'- AAG GCT TCC AGT TCT CAC TGC TGA -3' (rev) IER3 5'- TCT TTC TGC TGC TCA CCA TCG TCT -3' (fwd) 5'- GCT CCG AAG TCA GAT TAA AGG GCT -3' (rev) ALPL 5'- TCG CCT ACC AGC TCA TGC ATA ACA -3' (fwd) 5'- TGA AGC TCT TCC AGG TGT CAA CGA -3' (rev) GADD45A 5'- TCT GCA GAT CCA CTT CAC CCT GAT -3' (fwd) 5'- TGA ATG TGG ATT CGT CAC CAG CAC -3' (rev) SSX1 5'- AAG TCA CCC TCC CAC CTT TCA TGT -3' (fwd) 5'- ACC TGA ATC CTG CGG TTA TGG TCA -3' (rev) DDP7 5'- TCA GTG CCT ACC TGA GGA TGA AGT -3' (fwd) 5'- AGT CCT TGA TCT GTC GGA ACG CTT -3' (rev) FAPB3 5'- GCA TGA CCA AGC CTA CCA CAA TCA -3' (fwd) 5'- GCA GGT GAA CAA GTT TCC CTC CAT -3' (rev) TGFBI 5'- TGA GAG ACC TGC TGA ACA ACC ACA -3' (fwd) 5'- ATT GGA GAT GAT CGC CTT CCC GTT -3' (rev) NCALD 5'- AGG ACT TGC TGG AAA GCA CAG ACT -3' (fwd) 5'- GTG CGG AAG ACA TGC TCT GCA AAT -3' (rev) S100A2 5'- AAG GGA CTT CTG CAC AAG GAG C -3' (fwd) 5'- AAG GCA GAA CCA TTA GGC AGG -3' (rev) Supplemental Table 2 A: Doxorubicin Gene bank Gene Gene name Fold accesion symbol difference number NM_014367 E2IG5 growth and transformation-dependent protein 2.1 NM_017740 FLJ20279 zinc finger, DHHC domain containing 7 1.6 NM_024061 MGC5521 vav-1 interacting Kruppel-like protein 2.5 NM_006541 TXNL2 thioredoxin-like 2 1.9 NM_020640 RP42 RP42 homolog 2.0 NM_021975 RELA v-rel reticuloendotheliosis viral oncogene homolog A 1.8 NM_017646 IPT tRNA isopentenyltransferase 1 1.6 AB037760 ZER6 zinc finger protein 398 2.1 NM_000925 PDHB pyruvate dehydrogenase (lipoamide) beta 2.0 NM_007187 WBP4 WW domain binding protein 4 (formin binding protein 21) 2.0 NM_006704 SGT1 SGT1, suppressor of G2 allele of SKP1 (S. cerevisiae) 1.9 NM_004888 ATP6G1 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G isoform 1 1.7 NM_013379 DPP7 dipeptidylpeptidase 7 8.6 NM_014762 DHCR24 24-dehydrocholesterol reductase 2.1 NM_032565 EBRP emopamil binding related protein, delta8-delta7 sterol isomerase related protein 2.5 NM_015533 DKFZP586B1621 DKFZP586B1621 protein 2.3 NM_003366 UQCRC2 ubiquinol-cytochrome c reductase core protein II 1.8 1382894.51 2.2 NM_014751 KIAA0429 metastasis suppressor 1 4.8 NM_014720 SLK SNF1 sucrose nonfermenting like kinase (yeast) 2.9 NM_006716 ASK activator of S phase kinase 1.8 U57623 FABP3 Human fatty acid binding protein FABP gene, complete cds. 9.8 NM_004282 BAG2 BCL2-associated athanogene 2 1.8 AF400074 SFTPB Homo sapiens surfactant, pulmonary-associated protein B (SFTPB) gene, complete cds. 2.1 NM_003130 SRI sorcin 1.9 NM_001540 HSPB1 heat shock 27kDa protein 1 2.7 NM_022170 WBSCR1 Williams-Beuren syndrome chromosome region 1 1.8 NM_001151 SLC25A4 solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 6.9 AB007618 COX7A2L cytochrome c oxidase subunit VIIa polypeptide 2 like 10.8 AJ330090 Homo sapiens genomic sequence surrounding NotI site, clone NR1-WB20R. 2.2 U90878 PDLIM1 PDZ and LIM domain 1 (elfin) 6.1 NM_020992 PDLIM1 PDZ and LIM domain 1 (elfin) 8.8 NM_006022 TSC22 transforming growth factor beta-stimulated protein TSC-22 1.9 BE615983 STUB1 STIP1 homology and U-Box containing protein 1 3.9 NM_032312 MGC11061 hypothetical protein MGC11061 1.3 NM_004332 BPHL biphenyl hydrolase-like (serine hydrolase; breast epithelial mucin-associated antigen) 1.7 NM_005346 HSPA1B heat shock 70kDa protein 1B 2.2 M59830 HSPA1B Human MHC class III HSP70-2 gene (HLA), complete cds. 4.4 NM_000786 CYP51 cytochrome P450, family 51, subfamily A, polypeptide 1 2.5 NM_006530 GAS41 glioma-amplified sequence-41 2.1 NM_032027 BBP beta-amyloid binding protein precursor 1.7 AK025140 FLJ32421 hypothetical protein FLJ32421 1.7 NM_003379 VIL2 villin 2 (ezrin) 2.3 NM_019000 FLJ20152 hypothetical protein FLJ20152 3.4 NM_001252 TNFSF7 tumor necrosis factor (ligand) superfamily, member 7 9.7 NM_024417 FDXR ferredoxin reductase 2.1 U76542 PYCS pyrroline-5-carboxylate synthetase (glutamate gamma-semialdehyde synthetase) 1.6 U03851 CAPZA2 capping protein (actin filament) muscle Z-line, alpha 2 1.9 NM_014178 HSPC156 syntaxin binding protein 6 (amisyn) -7.1 NM_006854 KDELR2 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 -2.3 NM_001439 EXTL2 exostoses (multiple)-like 2 -2.1 NM_013989 DIO2 deiodinase, iodothyronine, type II -4.8 NM_018153 TEM8 anthrax toxin receptor 1 -2.3 NM_012098 ANGPTL2 angiopoietin-like 2 -7.3 NM_000900 MGP matrix Gla protein -21.5 NM_004370 COL12A1 collagen, type XII, alpha 1 -10.3 NM_020411 GAGED2 G antigen, family D, 2 -26.8 NM_006818 AF1Q ALL1-fused gene from chromosome 1q -3.7 NM_006042 HS3ST3A1 heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 -3.9 NM_018071 FLJ10357 -2.9 BI493312 TIRP TRIF-related adaptor molecule -1.9 AP003480 Homo sapiens genomic DNA, chromosome 8q23, clone: KB1970H2. -2.3 AK026977 MYH10 myosin, heavy polypeptide 10, non-muscle -4.2 NM_005576 LOXL1 lysyl oxidase-like 1 -4.7 NM_006417 MTAP44 interferon-induced protein 44 -7.0 NM_002192 INHBA inhibin, beta A (activin A, activin AB alpha polypeptide) -2.9 1446924.4 -6.0 BC007259 -4.7 NM_000358 TGFBI transforming growth factor, beta-induced, 68kDa -10.1 NM_001839 CNN3 calponin 3, acidic -2.7 NM_004899 BRE brain and reproductive organ-expressed (TNFRSF1A modulator) -2.3 NM_003528 H2BFQ histone 2, H2be -3.2 AK024362 LOC147650 hypothetical protein LOC147650 -3.5 AL110136 LOC440944 Homo sapiens mRNA; cDNA DKFZp564I112 (from clone DKFZp564I112). -2.3 NM_130467 PAGE-5 PAGE-5 protein -132.5 NM_005635 SSX1 synovial sarcoma, X breakpoint 1 -20.7 NM_003516 H2AFO histone 2, H2aa -2.4 NM_005367 MAGEA12 melanoma antigen, family A, 12 -6.6 NM_014185 MOG1 Homo sapiens RAN guanine nucleotide release factor (RANGNRF), mRNA. -2.6 NM_003254 TIMP1 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) -2.0 NM_024841 FLJ14213 hypothetical protein FLJ14213 -5.1 NM_005651 TDO2 tryptophan 2,3-dioxygenase -7.4 AB032957 KIAA1131 HECT domain containing 1 -1.6 NM_013390 TMEM2 transmembrane protein 2 -3.4 NM_002376 MARK3 MAP/microtubule affinity-regulating kinase 3 -1.9 NM_032041 NCALD neurocalcin delta -9.1 B: Cisplatin Gene bank Gene Gene name Fold accesion symbol difference number NM_005738 ARL4 ADP-ribosylation factor-like 4 -2.6 NM_020395 LOC57117 hypothetical nuclear factor SBBI22 -1.7 NM_020139 LOC56898 dehydrogenase/reductase (SDR family) member 6 -3.0 AB037752 SENP2 Start codon is not identified.; Homo sapiens mRNA for KIAA1331 protein, partial cds. -1.9 NM_001610 ACP2 acid phosphatase 2, lysosomal -3.3 AK024362 LOC147650 hypothetical protein LOC147650 -4.6 NM_001535 HRMT1L1 HMT1 hnRNP methyltransferase-like 1 (S. cerevisiae) -2.2 NM_002018 FLII flightless I homolog (Drosophila) -2.3 NM_022067 FLJ12707 chromosome 14 open reading frame 133 -1.7 NM_017976 FLJ10038 GA binding protein transcription factor, beta subunit 2, 47kDa -2.7 1446924.4 -5.7 NM_020411 GAGED2 G antigen, family D, 2 -16.0 BC007259 -4.4 AL110136 LOC440944 Homo sapiens mRNA; cDNA DKFZp564I112 (from clone DKFZp564I112). -2.5 NM_005635 SSX1 synovial sarcoma, X breakpoint 1 -12.9 NM_130467 PAGE-5 PAGE-5 protein -84.0 NM_005651 TDO2 tryptophan 2,3-dioxygenase -8.1 NM_024841 FLJ14213 hypothetical protein FLJ14213 -5.3 NM_006801 KDELR1 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 -2.4 AB032957 KIAA1131 HECT domain containing 1 -1.6 NM_013390 TMEM2 transmembrane protein 2 -3.5 NM_032041 NCALD neurocalcin delta -9.3 NM_003516 H2AFO histone 2, H2aa -2.0 NM_003528 H2BFQ histone 2, H2be -3.6 NM_033027 AXUD1 AXIN1 up-regulated 1 -2.2 1049490.1 -2.7 AK026181 PHLDA1 pleckstrin homology-like domain, family A, member 1 -6.3 NM_003873 NRP1 neuropilin 1 -4.9 AB050468 LIG1 leucine-rich repeats and immunoglobulin-like domains 1 -4.5 NM_000153 GALC galactosylceramidase (Krabbe disease) -8.0 NM_002391 MDK midkine (neurite growth-promoting factor 2) -2.8 NM_013360 ZNF222 zinc finger protein 222 -3.0 AB020643 KIAA0836 glucuronyl C5-epimerase -3.4 AI557212 SKIL SKI-like -1.7 NM_013230 CD24 CD24 antigen (small cell lung carcinoma cluster 4 antigen) -5.6 NM_017432 PTOV1 prostate tumor overexpressed gene 1 -2.0 NM_016224 SNX9 sorting nexin 9 2.0 NM_003345 UBE2I ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast) 1.6 NM_001236 CBR3 carbonyl reductase 3 3.3 NM_015415 DKFZP564B167 DKFZP564B167 protein 2.2 AK000596 HPCAL1 hippocalcin-like 1 2.6 NM_001280 CIRBP cold inducible RNA binding protein 2.1 NM_002906 RDX radixin 2.5 NM_000237 LPL lipoprotein lipase 13.7 NM_024703 FLJ22593 hypothetical protein FLJ10640 19.7 NM_005398 PPP1R3C protein phosphatase 1, regulatory (inhibitor) subunit 3C 3.3 NM_012425 RSU1 Ras suppressor protein 1 2.1 NM_080806 COL13A1 collagen, type XIII, alpha 1 7.6 NM_024061 MGC5521 vav-1 interacting Kruppel-like protein 3.3 NM_007274 HBACH brain acyl-CoA hydrolase 2.8 NM_013379 DPP7 dipeptidylpeptidase 7 11.7 NM_006054 RTN3 reticulon 3 2.0 NM_032565 EBRP emopamil binding related protein, delta8-delta7 sterol isomerase related protein 2.6 AJ131016 SCL Homo sapiens SCL gene locus. 1.8 NM_004526 MCM2 MCM2 minichromosome maintenance deficient 2, mitotin (S. cerevisiae) 2.3 NM_001667 ARL2 sorting nexin 15 2.8 NM_024084 TMEM223 transmembrane protein 223 5.4 AL832246 hnRNPA3 heterogeneous nuclear ribonucleoprotein A3 2.3 NM_005671 D8S2298E reproduction 8 1.9 NM_004494 HDGF hepatoma-derived growth factor (high-mobility group
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Comparison of Orthologs Across Multiple Species by Various Strategies
    COMPARISON OF ORTHOLOGS ACROSS MULTIPLE SPECIES BY VARIOUS STRATEGIES BY HUI LIU DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biophysics and Computational Biology in the Graduate College of the University of Illinois at Urbana-Champaign, 2014 Urbana, Illinois Doctoral Committee: Professor Eric Jakobsson, Chair, Director of Research Professor Gene E. Robinson Associate Professor Saurabh Sinha Assistant Professor Jian Ma Abstract Thanks to the improvement of genome sequencing technology, abundant multi-species genomic data now became available and comparative genomics continues to be a fast prospering filed of biological research. Through the comparison of genomes of different organisms, we can understand what, at the molecular level, distinguishes different life forms from each other. It shed light on revealing the evolution of biology. And it also helps to refine the annotations and functions of individual genomes. For example, through comparisons across mammalian genomes, we can give an estimate of the conserved set of genes across mammals and correspondingly, find the species-specific sets of genes or functions. However, comparative genomics can be feasible only if a meaningful classification of genes exists. A natural way to do so is to delineate sets of orthologous genes. However, debates exist about the appropriate way to define orthologs. It is originally defined as genes in different species which derive from speciation events. But such definition is not sufficient to derive orthologous genes due to the complexity of evolutionary events such as gene duplication and gene loss. While it is possible to correctly figure out all the evolutionary events with the true phylogenetic tree, the true phylogenetic tree itself is impractical to be inferred.
    [Show full text]
  • NICU Gene List Generator.Xlsx
    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2
    [Show full text]
  • Noelia Díaz Blanco
    Effects of environmental factors on the gonadal transcriptome of European sea bass (Dicentrarchus labrax), juvenile growth and sex ratios Noelia Díaz Blanco Ph.D. thesis 2014 Submitted in partial fulfillment of the requirements for the Ph.D. degree from the Universitat Pompeu Fabra (UPF). This work has been carried out at the Group of Biology of Reproduction (GBR), at the Department of Renewable Marine Resources of the Institute of Marine Sciences (ICM-CSIC). Thesis supervisor: Dr. Francesc Piferrer Professor d’Investigació Institut de Ciències del Mar (ICM-CSIC) i ii A mis padres A Xavi iii iv Acknowledgements This thesis has been made possible by the support of many people who in one way or another, many times unknowingly, gave me the strength to overcome this "long and winding road". First of all, I would like to thank my supervisor, Dr. Francesc Piferrer, for his patience, guidance and wise advice throughout all this Ph.D. experience. But above all, for the trust he placed on me almost seven years ago when he offered me the opportunity to be part of his team. Thanks also for teaching me how to question always everything, for sharing with me your enthusiasm for science and for giving me the opportunity of learning from you by participating in many projects, collaborations and scientific meetings. I am also thankful to my colleagues (former and present Group of Biology of Reproduction members) for your support and encouragement throughout this journey. To the “exGBRs”, thanks for helping me with my first steps into this world. Working as an undergrad with you Dr.
    [Show full text]
  • Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets
    Research JAMA Neurology | Original Investigation Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets Demis A. Kia, MBBS; David Zhang, MSc; Sebastian Guelfi, PhD; Claudia Manzoni, PhD; Leon Hubbard, PhD; Regina H. Reynolds, MSc; Juan Botía, PhD; Mina Ryten, MD; Raffaele Ferrari, PhD; Patrick A. Lewis, PhD; Nigel Williams, PhD; Daniah Trabzuni, PhD; John Hardy, PhD; Nicholas W. Wood, PhD; for the United Kingdom Brain Expression Consortium (UKBEC) and the International Parkinson’s Disease Genomics Consortium (IPDGC) Supplemental content IMPORTANCE Substantial genome-wide association study (GWAS) work in Parkinson disease (PD) has led to the discovery of an increasing number of loci shown reliably to be associated with increased risk of disease. Improved understanding of the underlying genes and mechanisms at these loci will be key to understanding the pathogenesis of PD. OBJECTIVE To investigate what genes and genomic processes underlie the risk of sporadic PD. DESIGN AND SETTING This genetic association study used the bioinformatic tools Coloc and transcriptome-wide association study (TWAS) to integrate PD case-control GWAS data published in 2017 with expression data (from Braineac, the Genotype-Tissue Expression [GTEx], and CommonMind) and methylation data (derived from UK Parkinson brain samples) to uncover putative gene expression and splicing mechanisms associated with PD GWAS signals. Candidate genes were further characterized using cell-type specificity, weighted gene coexpression networks, and weighted protein-protein interaction networks. MAIN OUTCOMES AND MEASURES It was hypothesized a priori that some genes underlying PD loci would alter PD risk through changes to expression, splicing, or methylation.
    [Show full text]
  • The University of Chicago Genetic Services Laboratories Labolaboratories
    The University of Chicago Genetic Services Laboratories LaboLaboratories5841 S. Maryland Ave., Rm. G701, MC 0077, Chicago, Illinois 60637 3637 [email protected] dnatesting.uchicago.edu CLIA #: 14D0917593 CAP #: 18827-49 Next Generation Sequencing Panel for Albinism Clinical Features: Albinism is a group of inherited disorders in which melanin biosynthesis is reduced or absent [1]. The lack or reduction in pigment can affect the eyes, skin and hair, or only the eyes. In addition, there are several syndromic forms of albinism in which the hypopigmented and visual phenotypes are seen in addition to other systems involvement [2]. Our Albinism Sequencing Panel includes sequence analysis of all 20 genes listed below. Our Albinism Deletion/Duplication Panel includes sequence analysis of all 20 genes listed below. Albinism Sequencing Panel Chediak- Griscelli Oculocutaneous Ocular Hermansky Pudlak syndrome Higashi syndrome Albinism Albinism syndrome TYR SLC45A2 GPR143 HPS1 HPS4 DTNBP1 LYST MYO5A OCA2 SLC24A5 AP3B1 HPS5 BLOC1S3 RAB27A TYRP1 C10ORF11 HPS3 HPS6 BLOC1S6 MLPH Oculocutaneous Albinism Oculocutaneous albinism (OCA) is a genetically heterogeneous congenital disorder characterized by decreased or absent pigmentation in the hair, skin, and eyes. Clinical features can include varying degrees of congenital nystagmus, hypopigmentation and translucency, reduced pigmentation of the retinal pigment epithelium and foveal hypoplasia. Vision acuity is typically reduced and refractive errors, color vision impairment and photophobia also occur [3]. Gene Clinical Features Details TYR Albinism, OCA1 is caused by mutations in the tyrosinase gene, TYR. Mutations completely oculocutaneous, abolishing tyrosinase activity result in OCA1A, while mutations rendering some type I enzyme activity result in OCA1B allowing some accumulation of melanin pigment production throughout life.
    [Show full text]
  • Molecular Diagnostic Requisition
    BAYLOR MIRACA GENETICS LABORATORIES SHIP TO: Baylor Miraca Genetics Laboratories 2450 Holcombe, Grand Blvd. -Receiving Dock PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bmgl.com Houston, TX 77021-2024 Phone: 713-798-6555 MOLECULAR DIAGNOSTIC REQUISITION PATIENT INFORMATION SAMPLE INFORMATION NAME: DATE OF COLLECTION: / / LAST NAME FIRST NAME MI MM DD YY HOSPITAL#: ACCESSION#: DATE OF BIRTH: / / GENDER (Please select one): FEMALE MALE MM DD YY SAMPLE TYPE (Please select one): ETHNIC BACKGROUND (Select all that apply): UNKNOWN BLOOD AFRICAN AMERICAN CORD BLOOD ASIAN SKELETAL MUSCLE ASHKENAZIC JEWISH MUSCLE EUROPEAN CAUCASIAN -OR- DNA (Specify Source): HISPANIC NATIVE AMERICAN INDIAN PLACE PATIENT STICKER HERE OTHER JEWISH OTHER (Specify): OTHER (Please specify): REPORTING INFORMATION ADDITIONAL PROFESSIONAL REPORT RECIPIENTS PHYSICIAN: NAME: INSTITUTION: PHONE: FAX: PHONE: FAX: NAME: EMAIL (INTERNATIONAL CLIENT REQUIREMENT): PHONE: FAX: INDICATION FOR STUDY SYMPTOMATIC (Summarize below.): *FAMILIAL MUTATION/VARIANT ANALYSIS: COMPLETE ALL FIELDS BELOW AND ATTACH THE PROBAND'S REPORT. GENE NAME: ASYMPTOMATIC/POSITIVE FAMILY HISTORY: (ATTACH FAMILY HISTORY) MUTATION/UNCLASSIFIED VARIANT: RELATIONSHIP TO PROBAND: THIS INDIVIDUAL IS CURRENTLY: SYMPTOMATIC ASYMPTOMATIC *If family mutation is known, complete the FAMILIAL MUTATION/ VARIANT ANALYSIS section. NAME OF PROBAND: ASYMPTOMATIC/POPULATION SCREENING RELATIONSHIP TO PROBAND: OTHER (Specify clinical findings below): BMGL LAB#: A COPY OF ORIGINAL RESULTS ATTACHED IF PROBAND TESTING WAS PERFORMED AT ANOTHER LAB, CALL TO DISCUSS PRIOR TO SENDING SAMPLE. A POSITIVE CONTROL MAY BE REQUIRED IN SOME CASES. REQUIRED: NEW YORK STATE PHYSICIAN SIGNATURE OF CONSENT I certify that the patient specified above and/or their legal guardian has been informed of the benefits, risks, and limitations of the laboratory test(s) requested.
    [Show full text]
  • Celecoxib Treatment Alters the Gene Expression Profile of Normal Colonic Mucosa
    1382 Celecoxib Treatment Alters the Gene Expression Profile of Normal Colonic Mucosa Oleg K. Glebov,1 Luz M. Rodriguez,1 Patrick Lynch,4 Sherri Patterson,4 Henry Lynch,5 Kenneth Nakahara,1 Jean Jenkins,1 Janet Cliatt,1 Casey-Jo Humbyrd,1 John DeNobile,3 Peter Soballe,3 Steven Gallinger,6 Aby Buchbinder,7 Gary Gordon,8 Ernest Hawk,2 and Ilan R. Kirsch1 1Genetics Branch, Center for Cancer Research; 2Division of Cancer Prevention, National Cancer Institute; 3Surgery Department, National Naval Medical Center, Bethesda, Maryland; 4University of Texas M.D. Anderson Cancer Center, Houston, Texas; 5Creighton University, Omaha, Nebraska; 6University of Toronto, Toronto, Ontario, Canada; 7Pharmacia, Peapack, New Jersey; and 8Ovation Pharma, Lincolnshire, Illinois Abstract A clinical trial was recently conducted to evaluate the safety Twenty-three of 25 pairs of colon biopsies taken before and efficacy of a selective inhibitor of cyclooxygenase-2 and after celecoxib treatment can be classified correctly (celecoxib) in hereditary nonpolyposis colon cancer by the pattern of gene expression in a leave-one-out patients. In a randomized, placebo-controlled phase I/II cross-validation. Immune response, particularly T- and B- multicenter trial, hereditary nonpolyposis colon cancer lymphocyte activation and early steps of inflammatory patients and gene carriers received either celecoxib at one reaction, cell signaling and cell adhesion, response to stress, of two doses or placebo. The goal was to evaluate the effects transforming growth factor-B signaling, and regulation of of these treatment arms on a number of endoscopic and apoptosis, are the main biological processes targeted by tissue-based biomarker end points after 12 months of celecoxib as shown by overrepresentation analysis of the treatment.
    [Show full text]
  • Supplementary Data
    Supplementary Fig. 1 A B Responder_Xenograft_ Responder_Xenograft_ NON- NON- Lu7336, Vehicle vs Lu7466, Vehicle vs Responder_Xenograft_ Responder_Xenograft_ Sagopilone, Welch- Sagopilone, Welch- Lu7187, Vehicle vs Lu7406, Vehicle vs Test: 638 Test: 600 Sagopilone, Welch- Sagopilone, Welch- Test: 468 Test: 482 Responder_Xenograft_ NON- Lu7860, Vehicle vs Responder_Xenograft_ Sagopilone, Welch - Lu7558, Vehicle vs Test: 605 Sagopilone, Welch- Test: 333 Supplementary Fig. 2 Supplementary Fig. 3 Supplementary Figure S1. Venn diagrams comparing probe sets regulated by Sagopilone treatment (10mg/kg for 24h) between individual models (Welsh Test ellipse p-value<0.001 or 5-fold change). A Sagopilone responder models, B Sagopilone non-responder models. Supplementary Figure S2. Pathway analysis of genes regulated by Sagopilone treatment in responder xenograft models 24h after Sagopilone treatment by GeneGo Metacore; the most significant pathway map representing cell cycle/spindle assembly and chromosome separation is shown, genes upregulated by Sagopilone treatment are marked with red thermometers. Supplementary Figure S3. GeneGo Metacore pathway analysis of genes differentially expressed between Sagopilone Responder and Non-Responder models displaying –log(p-Values) of most significant pathway maps. Supplementary Tables Supplementary Table 1. Response and activity in 22 non-small-cell lung cancer (NSCLC) xenograft models after treatment with Sagopilone and other cytotoxic agents commonly used in the management of NSCLC Tumor Model Response type
    [Show full text]
  • New Tests 2 Test Updates 4 CPT Code Updates 11 Deleted Tests 11 Diagnostics Update Volume XXI, No
    Volume XXI, No. 6 JUNE 2021 MONTHLY TEST UPDATES Diagnostics Update New Tests 2 Test Updates 4 CPT Code Updates 11 Deleted Tests 11 Diagnostics Update Volume XXI, No. 6 | JUNE 2021 New Tests Use Anti-DFS70 antibodies may help identify individuals who do not have an Anti-Carbamylated Protein (CarP) Antibody 520311 ANA-associated Autoimmune Rheumatic Disease (AARD) especially in the absence of significant clinical findings.1 Anti-DFS70 Ab, especially when positive CPT 83516 in isolation (i.e. in the absence of AARD-associated autoantibodies), may Synonyms Anti-CarP antigen antibody; RA marker prevent unnecessary referrals and examinations of ANA-positive individuals.2 Special Instructions This test has not been approved for NY state clients. Limitations This test should be used with clinical findings and other Specimen Serum autoimmune testing; it cannot be used alone to rule out autoimmune disease. Volume 1 mL This test was developed and its performance characteristics determined Minimum Volume 0.5 mL by Labcorp. It has not been cleared or approved by the Food and Drug Container Red-top tube; serum from red-top tube; serum from a gel tube; or Administration. serum gel tube Methodology Enzyme-linked immunosorbent assay (ELISA) Collection Separate serum from cells within one hour of collection. Transfer to a Additional Information Anti-DFS70 antibodies target the dense fine speckled plastic transport tube before shipping. protein of 70 kDa which is identical to Lens Epithelium-Derived Growth Factor Storage Instructions Refrigerate or freeze. or transcription co-activator p75 (LEDGFp75). They are detectable in 2% to 22% Stability of healthy individuals and in less than 1% of patients with AARD are of unknown Temperature Period clinical significance.
    [Show full text]
  • Eye Disorders Requisition
    BAYLOR MIRACA GENETICS LABORATORIES SHIP TO: Baylor Miraca Genetics Laboratories 2450 Holcombe, Grand Blvd. -Receiving Dock PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bmgl.com Houston, TX 77021-2024 Phone: 713-798-6555 INHERITED EYE DISORDERS REQUISITION PATIENT INFORMATION SAMPLE INFORMATION NAME: DATE OF COLLECTION: / / LAST NAME FIRST NAME MI MM DD YY HOSPITAL#: ACCESSION#: DATE OF BIRTH: / / GENDER (Please select one): FEMALE MALE MM DD YY SAMPLE TYPE (Please select one): ETHNIC BACKGROUND (Select all that apply): UNKNOWN BLOOD AFRICAN AMERICAN CORD BLOOD ASIAN SKELETAL MUSCLE ASHKENAZIC JEWISH MUSCLE EUROPEAN CAUCASIAN -OR- DNA (Specify Source): HISPANIC NATIVE AMERICAN INDIAN PLACE PATIENT STICKER HERE OTHER JEWISH OTHER (Specify): OTHER (Please specify): REPORTING INFORMATION ADDITIONAL PROFESSIONAL REPORT RECIPIENTS PHYSICIAN: NAME: INSTITUTION: PHONE: FAX: PHONE: FAX: NAME: EMAIL (INTERNATIONAL CLIENT REQUIREMENT): PHONE: FAX: INDICATION FOR STUDY SYMPTOMATIC (Summarize below.): *FAMILIAL MUTATION/VARIANT ANALYSIS: COMPLETE ALL FIELDS BELOW AND ATTACH THE PROBAND'S REPORT. GENE NAME: ASYMPTOMATIC/POSITIVE FAMILY HISTORY: (ATTACH FAMILY HISTORY) MUTATION/UNCLASSIFIED VARIANT: RELATIONSHIP TO PROBAND: THIS INDIVIDUAL IS CURRENTLY: SYMPTOMATIC ASYMPTOMATIC *If family mutation is known, complete the FAMILIAL MUTATION/ VARIANT ANALYSIS section. NAME OF PROBAND: ASYMPTOMATIC/POPULATION SCREENING RELATIONSHIP TO PROBAND: OTHER (Specify clinical findings below): BMGL LAB#: A COPY OF ORIGINAL RESULTS ATTACHED IF PROBAND TESTING WAS PERFORMED AT ANOTHER LAB, CALL TO DISCUSS PRIOR TO SENDING SAMPLE. A POSITIVE CONTROL MAY BE REQUIRED IN SOME CASES. REQUIRED: NEW YORK STATE PHYSICIAN SIGNATURE OF CONSENT I certify that the patient specified above and/or their legal guardian has been informed of the benefits, risks, and limitations of the laboratory test(s) requested.
    [Show full text]
  • Effects of Chronic Stress on Prefrontal Cortex Transcriptome in Mice Displaying Different Genetic Backgrounds
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector J Mol Neurosci (2013) 50:33–57 DOI 10.1007/s12031-012-9850-1 Effects of Chronic Stress on Prefrontal Cortex Transcriptome in Mice Displaying Different Genetic Backgrounds Pawel Lisowski & Marek Wieczorek & Joanna Goscik & Grzegorz R. Juszczak & Adrian M. Stankiewicz & Lech Zwierzchowski & Artur H. Swiergiel Received: 14 May 2012 /Accepted: 25 June 2012 /Published online: 27 July 2012 # The Author(s) 2012. This article is published with open access at Springerlink.com Abstract There is increasing evidence that depression signaling pathway (Clic6, Drd1a,andPpp1r1b). LA derives from the impact of environmental pressure on transcriptome affected by CMS was associated with genetically susceptible individuals. We analyzed the genes involved in behavioral response to stimulus effects of chronic mild stress (CMS) on prefrontal cor- (Fcer1g, Rasd2, S100a8, S100a9, Crhr1, Grm5,and tex transcriptome of two strains of mice bred for high Prkcc), immune effector processes (Fcer1g, Mpo,and (HA)and low (LA) swim stress-induced analgesia that Igh-VJ558), diacylglycerol binding (Rasgrp1, Dgke, differ in basal transcriptomic profiles and depression- Dgkg,andPrkcc), and long-term depression (Crhr1, like behaviors. We found that CMS affected 96 and 92 Grm5,andPrkcc) and/or coding elements of dendrites genes in HA and LA mice, respectively. Among genes (Crmp1, Cntnap4,andPrkcc) and myelin proteins with the same expression pattern in both strains after (Gpm6a, Mal,andMog). The results indicate significant CMS, we observed robust upregulation of Ttr gene contribution of genetic background to differences in coding transthyretin involved in amyloidosis, seizures, stress response gene expression in the mouse prefrontal stroke-like episodes, or dementia.
    [Show full text]